Clinical Research Directory

Inclusion Criteria: Age 12 months or younger at enrollment. First presentation to the hemangioma specialty clinic for systematic evaluation. Clinical diagnosis of infantile hemangioma with minimal or arrested growth or typical infantile hemangioma. No prior oral beta-blocker therapy, laser therapy, surgery, or other treatment that may substantially affect the baseline lesion status or initial management recommendation. Availability of standardized clinical photographs and complete lesion documentation for risk assessment. Written informed consent provided by a parent or legal guardian. Parent or legal guardian willing to participate in scheduled follow-up. Exclusion Criteria: * Congenital hemangioma, capillary malformation, venous malformation, arteriovenous malformation, or another non-infantile hemangioma vascular anomaly. Prior systemic therapy, laser therapy, surgery, or other treatment before baseline evaluation that substantially alters lesion status or would affect the initial management recommendation. Missing key data required for the primary outcome or risk assessment, including lesion location, lesion size, standardized clinical photographs, or the initial management recommendation. Severe comorbid condition that makes the initial management recommendation primarily determined by non-hemangioma-related factors. Parent or legal guardian unwilling or unable to provide informed consent or comply with follow-up. For the confirmed IH-MAG analysis, suspected IH-MAG later reclassified because proliferative components involve 25% or more of the total lesion area.